Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant immunotherapy with or without tumor-bed radiotherapy for breast cancer
ChiCTR2500098954Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in breast cancer (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Residual Cancer Burden after surgery. Started Mar 2025; status: recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500098954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098954.